Loading...
Many patients on successful antiretroviral regimens experience transient low-level virologic rebound, prompting anxiety among them and their providers alike. These data from a large European cohort examine the consequences of such events.
Of the 11,912 HIV-infected patients enrolled in the cohort as of February 2006, 4447 were chosen for this analysis because they were virologically suppressed and were treatment naive before initiating their current regimen. Total follow-up time was 11,187 person-years, with an average of 3.3 viral-load measurements per person-year. Seventy-four percent of all virologic “episodes” were defined as suppression (<50 copies/mL), 21.2% as low-level viremia (50–1000 copies/mL), and 4.6% as high-level viremia (>100…